Expected earnings - Actuate Therapeutics Inc.
Source: US Earnings Reports
Actuate Therapeutics Inc. (ACTU) is expected to report $-0.24 for Q4 2025
Actuate Therapeutics Inc.
NASDAQ: ACTU
ACTU Trading
-2.31% G/L:
$1.90 Last:
30,171 Volume:
$2 Open:
ACTU Latest News
June 01, 2026 07:00:00 am
Actuate Therapeutics Announces ASCO Poster Presentations Demonstrating Compelling Clinical and Biomarker Data for Elraglusib in First-Line Metastatic Pancreatic Cancer
May 11, 2026 07:00:00 am
Actuate Therapeutics Announces FDA Clearance of IND for Oral Elraglusib and Strategic Initiatives to Advance the Elraglusib Development Program
May 06, 2026 08:45:00 am
Actuate Therapeutics Announces Key Appointment of Industry Veteran to Board of Directors
ACTU Stock Data
$99,249,011
7,126,404
3.89%
13
N/A
Biotechnology & Life Sciences
Healthcare
US
Fort Worth
